Chinese Biotech Company focuses on creating groundbreaking therapies aimed at solving critical and currently unmet medical challenges. Leveraging advanced biotechnological methods, the firm strives to transform patient outcomes on a global scale. Its research pipeline is supported by a team of world-class scientists, and the company plans to accelerate multiple clinical trials in the near term. The newly raised capital will also fund team expansion and strategic partnerships intended to broaden the firm’s reach. Backing from Singapore’s state investment arm, Temasek, underscores strong investor confidence in the company’s potential. Although detailed operating metrics such as revenue or user numbers were not disclosed, the successful Series B round highlights the company’s solid financial backing and growth trajectory.

Total raised

$108M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2025